Cannabis Science Inc. Reports on Prospective Life Saving Treatments for H1N1 Swine Flu and H5N1 Bird Flu in View of the Current Global Threat
SAN FRANCISCO--(BUSINESS WIRE)--Cannabis Science Inc. (OTCBB: GFON.OB), an emerging pharmaceutical cannabis company, reported today on the current state of development of its whole-cannabis lozenge in response to Homeland Security Administration Secretary Janet Napolitano's declaration of a public health emergency to deal with the emerging Swine Flu pandemic. The Company's non-toxic lozenge has properties that could alleviate many of the symptoms and harmful effects of the H5N1 bird flu and H1N1 swine flu viruses, and has offered its assistance to HSA today in a letter to Secretary Napolitano.
Cannabis Science Inc., President & CEO, Steven W. Kubby said, "We have the science and preliminary anecdotal results confirming the anti-inflammatory properties of our new lozenges and indicating they may present an effective and non-toxic treatment for minimizing the symptoms and harm from influenza infections. Our lozenges appear to down-regulate the body's excessive inflammatory response to the influenza virus, which could reduce the deadly consequences of an infection into something that is more like a common cold. Because of my cancer and diminished auto-immune functions, even common influenza is a deadly threat, and I've had incredible symptomatic relief with the lozenge."
Dr. Robert J. Melamede, Director and Chief Science Officer, stated, "The influenza virus has a unique genetic make up that, in combination with its replicative machinery, has an extraordinary capacity to mutate. As a result, the high lethality of some strains can be attributed to the resulting adult respiratory distress syndrome (ARDS). ARDS is caused by an excessive immune inflammatory response driven by Tumor Necrosis Factor (TNF) that leads to the death of respiratory epithelial cells and resulting organ failure. Endocannabinoids are nature's way of controlling TNF activity. Existing peer reviewed publications have shown that phytocannabinoids can prevent this cell death by mimicking the endocannabinoids that nature has selected to prevent excessive inflammatory immune responses."
Dr. Melamede, who is also a researcher and past Chairman of the Biology Department at the University of Colorado Springs (UCCS), cautioned, "Smoked marijuana will not effectively prevent the excessive inflammatory response, despite delivering the beneficial pharmacological agents, due to the irritating, pro-inflammatory nature of smoke. In fact, I believe it will make things worse and should be avoided by infected individuals."
Mr. Kubby added, "If a swine or bird flu pandemic emerges -- and everyone seems to think that it is just a matter of when, not if --, there is simply no time for the usual bureaucratic process. With emergency government approval, we can legally access the huge supply of medical cannabis available in California to produce millions of life saving doses within a relatively short period of time."
Dr. Melamede furthermore stated, "Based upon recent discoveries regarding the role that endocannabinoid system plays in maintaining human health, we have a unique solution to the looming threat posed by deadly influenza strains that we believe, if implemented, could save millions of lives. We will strive for an emergency review of our cannabis extract-based lozenge because we believe its availability will prevent many of the deaths associated with the hyper-inflammatory response associated with known lethal strains of the influenza virus. Current anti-influenza medications have a demonstrated decreased effectiveness against some of these lethal variants. Mankind cannot wait for the emergency situation to materialize. We must be proactive in gaining the necessary governmental approvals to test, and pending the outcome of our studies, produce our lozenge."
Mr. Richard Cowan, Director and CFO, who recently spoke in Mexico City to a conference sponsored by the Mexican Congress, stated, "I believe the Mexican Congress recognizes that doctors should be able to prescribe medical cannabis. We are prepared to work with the government of Mexico to produce similar medical cannabis products to help fight the outbreak there. We look forward to working with Government officials, including Homeland Security, to help advance our treatments for these outbreaks in Mexico, Canada, the USA, and around the world."
About the H5N1 Bird Flu and H1N1 Swine Flu Strains
The H5N1 bird flu currently has 63% lethality. A swine-derived H1N1 strain was responsible for 20,000,000 influenza associated deaths in 1918 (more than killed by World War I). The current lethal outbreak of swine flu (H1N1) in Mexico has killed over 80 people and infected more than 1,400 others. There are 20 confirmed cases in the United States, with reports of infections in Texas, New York, Ohio, California and Kansas. Additional reports identify possible cases in New Zealand, Canada, Spain, France and Israel. The H1N1 Swine flu is a porcine respiratory disease caused by type A flu viruses. Human cases occur in people who are around pigs, but an infected person can transmit the disease to another person. Symptoms include a high fever, body aches, coughing, sore throat and respiratory congestion.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," "intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.